Trial Profile
A Randomized Study to Evaluate the Safety and Efficacy of Loading Dose of Bondronat Versus Standard Dose of Bondronat in Patients With Lung Cancer and Skeletal Metastasis Experiencing Moderate to Severe Pain
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 19 Feb 2016
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Cancer metastases; Lung cancer
- Focus Therapeutic Use
- 10 Jun 2008 Status change from initiated to discontinued according to clinicaltrials.gov, due to difficulty recruiting suitable patients.
- 20 Sep 2007 Updated start date fromo NCT.
- 12 Jul 2007 New trial record.